| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Human observational/clinical studies conducted primarily in Russia for ischemic stroke, cognitive impairment, and neuroprotection. Russian regulatory approved. No Western Phase III RCT. Observational/Phase II equivalent. |
15 / 25 |
| Sample Size | Individual Russian trials typically 60-120 patients. Cumulative sample moderate but split across multiple small studies. |
4 / 20 |
| Replication | Overwhelmingly single-institution (Russian research groups, often Beritashvili Center or related). Independent replication outside Russia is essentially absent. Russian Literature Note applies. |
10 / 20 |
| Journal Impact Factor | Published in Bulletin of Experimental Biology and Medicine (Russian journal, low Western IF), Zhurnal Nevrologii i Psikhiatrii (Russian), and occasional English-language journals with IF ~2-3. |
4 / 15 |
| Funding Independence | Russian academic and government funded. Independent from commercial pharmaceutical interests but narrow funding base. |
4 / 10 |
| Population Diversity | Russian patient populations predominantly. Limited geographic and ethnic diversity from Western perspective. Moderate score given consistency within the studied population. |
3 / 5 |
| Researcher h-Index | Russian academic researchers with moderate h-Indexes in Western databases. h-Index often undercounted for Russian researchers due to journal indexing gaps — acknowledged in the Russian Literature Note. |
2 / 5 |